Press Releases Presentations & Publications >

INTARCIA PRESENTATIONS & PUBLICATIONS   Jun 28, 2010 Comparing ITCA 650, Continuous Subcutaneous Delivery of Exenatide Via DUROS® Device, vs Twice Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes Nov 06, 2009 Stability of ITCA 650 for Continuous Subcutaneous Delivery of Exenative at Body Temperature for 12 Months Nov 06, 2009 Continuous Subcutaneous Delivery of Exenative via ITCA 650 Lowers Plasma Glucose, HbA1c and Reduces Weight in a 28-day Phase 1b Study in Type 2 Diabetes Sept 30, 2009 ESAD Presentation: A Phase 1b Study of ITCA 650: Continuous Subcutaneous Delivery of Exenatide via DUROS® Device Lowers Fasting and Postprandial Plasma Glucose Jun 06, 2009 ADA 2009 Late Breaker: A Phase 1b Study of ITCA 650: Continuous Subcutaneous Delivery of Exenatide via DUROS® Device Lowers Fasting and Postprandial Plasma Glucose Nov 18, 2008 Intarcia Therapeutics, Inc.  Presents DUROS® Delivery of Hepatitis C and type 2 diabetes therapies at AAPS conference May 01, 2008 DUROS® Technology Delivers Pepties and Proteins at Consistent Rate Continuously for 3 to 12 Months